Rohit Aggarwal, MD,MS (he/him/his)
Professor
University of Pittsburgh
Pittsburgh, PA, United States
Disclosure information not submitted.
Lisa Christopher-Stine, MD, MPH
Professor
Johns Hopkins University
Baltimore, Maryland, United States
Disclosure information not submitted.
*Welcome and Introduction (Rohit Aggarwal)
*Unraveling the Mechanisms of Action of Immunoglobulins in Dermatomyositis (Lisa Christopher-Stine)
*Further Learnings from Phase 3 Clinical Data (Rohit Aggarwal)
* Q&A and Closing Remarks (Lisa Christopher-Stine & Rohit Aggarwal)
While the use of Intravenous Immunoglobulin (IVIg) in autoimmune disorders like dermatomyositis is known for its effectiveness and widely used in clinical practice, the precise molecular mechanisms underlying its therapeutic effects have not been fully elucidated. During this session Prof. Lisa Christopher-Stine will provide a comprehensive overview of immunoglobulin therapy, exploring the complex, multi-faceted mechanisms through which IVIg works in managing conditions such as dermatomyositis, as well as in mitigating infection risks for dermatomyositis patients undergoing other immunosuppressive therapy. Through this session, attendees will gain a deeper understanding of how to effectively utilize IVIg to enhance patient outcomes. Prof. Rohit Aggarwal will further illustrate the therapeutic potential of IVIg by sharing insights from phase 3 clinical data in dermatomyositis. After discussing how IVIg has influenced treatment approaches for dermatomyositis, his presentation will focus on the impact of baseline variables, such as autoantibody status, on treatment response. The session will conclude with an interactive discussion, inviting the audience to engage with the faculty. For healthcare professionals only. This program is developed and offered by Octapharma. This is not an official program of the American College of Rheumatology.
Non-CME